Unità Operativa di Interventistica Cardiovascolare, Pineta Grande Hospital, Castel Volturno, Italy.
Unità Operativa di Emodinamica, Santa Lucia Hospital, San Giuseppe Vesuviano, Italy.
Am J Cardiol. 2024 Oct 1;228:24-33. doi: 10.1016/j.amjcard.2024.07.037. Epub 2024 Aug 5.
Transcatheter mitral edge-to-edge repair (TEER) with transcatheter devices has become a mainstay in the minimally invasive treatment of patients with severe mitral regurgitation at increased surgical risk. Despite its apparently favorable risk profile, there is uncertainty on the risk and features of cerebrovascular accidents (CVAs) early and long after transcatheter mitral valve repair. We aimed to appraise the incidence and predictors of CVA in patients who underwent TEER. We explicitly queried the data set of an ongoing multicenter prospective observational study dedicated to TEER with MitraClip (Abbott Vascular, Santa Clara, California). The incidence of CVAs after TEER was formally appraised, and we explored potential predictors of such events. Descriptive, bivariate, and diagnostic accuracy analyses were performed. Of 2,238 patients who underwent TEER, CVAs occurred in 33 patients (1.47% [95% confidence interval 1.02% to 2.06%]), including 6 (0.27% [0.10% to 0.58%]) in-hospital strokes and 27 events after discharge (0.99% [0.66% to 1.44%]), over a median follow-up of 14 months. Most CVAs were major ischemic strokes during and after the in-hospital phase. Overall, CVAs were more common in patients with atrial fibrillation (p = 0.018), renal dysfunction (p = 0.032), higher EuroSCORE II (p = 0.033), and, as expected, higher CHA2DS2-VASc score (p = 0.033), despite the limited prognostic accuracy of the score. Notably, the occurrence of CVA did not confer a significantly increased risk of long-term (p = 0.136) or cardiac death (p = 0.397). The incidence of CVA in patients who underwent TEER is low, with most events occurring after discharge and being associated with preexisting risk features. These findings, although reassuring on the safety of TEER, call for proactive antithrombotic therapy whenever CVA risk is increased before and after TEER.
经导管二尖瓣缘对缘修复术(TEER)联合经导管装置已成为治疗高手术风险重度二尖瓣反流患者的微创治疗的主要手段。尽管其风险状况显然较好,但在经导管二尖瓣修复术后早期和长期,对中风(CVA)的风险和特征仍存在不确定性。我们旨在评估行 TEER 的患者中 CVA 的发生率和预测因素。我们明确查询了一项正在进行的多中心前瞻性观察性研究的数据集,该研究专门针对 MitraClip(雅培血管,加利福尼亚州圣克拉拉)进行 TEER。正式评估了 TEER 后 CVA 的发生率,并探讨了此类事件的潜在预测因素。进行了描述性、双变量和诊断准确性分析。在接受 TEER 的 2238 名患者中,33 名患者发生 CVA(1.47%[95%置信区间 1.02%至 2.06%]),包括 6 例(0.27%[0.10%至 0.58%])住院期间中风和 27 例出院后(0.99%[0.66%至 1.44%])事件,中位随访时间为 14 个月。大多数 CVA 是住院期间和之后的主要缺血性中风。总体而言,房颤(p=0.018)、肾功能不全(p=0.032)、较高的 EuroSCORE II(p=0.033)患者中 CVA 更常见,并且正如预期的那样,CHA2DS2-VASc 评分较高(p=0.033),尽管评分的预后准确性有限。值得注意的是,CVA 的发生并未显著增加长期(p=0.136)或心脏死亡(p=0.397)的风险。TEER 患者 CVA 的发生率较低,大多数事件发生在出院后,与先前存在的风险特征有关。这些发现虽然对 TEER 的安全性令人放心,但在 TEER 前后增加 CVA 风险时,应积极进行抗血栓治疗。